{"id":477443,"date":"2020-04-02T12:16:01","date_gmt":"2020-04-02T12:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477443"},"modified":"2020-04-02T12:16:01","modified_gmt":"2020-04-02T12:16:01","slug":"refractory-angina-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/refractory-angina-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_477443.html","title":{"rendered":"Refractory Angina Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Refractory<\/a><\/div>\n

 <\/p>\n

DelveInsight has launched a new report on Refractory Angina Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Refractory Angina market report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Refractory Angina treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Refractory Angina (RA)<\/strong> is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart.Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease(CAD). <\/p>\n

Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causespoor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization. Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong><\/em>Free sample page<\/a><\/p>\n

Epidemiology<\/strong><\/em><\/p>\n

The Refractory Angina epidemiology division provide insights about historical and current Refractory Angina patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken<\/p>\n

Report key facts:-<\/strong><\/em><\/p>\n

1.  <\/strong><\/em>As per Delveinsight’s estimates, the total prevalent cases of Refractory Angina in 7 major markets ranges from 29,17,196 <\/strong>in 2017.<\/p>\n

2. According to the Delveinsight’s analysts, the United States accounted for most prevalent cases of RA in 7MM with 19,05,602<\/strong>  cases in 2017.<\/p>\n

3. Japan accounted for 27,432<\/strong> cases in 2017 which are expected to grow during the study period (2017–2030).<\/p>\n

Refractory Angina (RA)is a chronic disease characterized by the presence of persistent angina and patients with RA defined as being ‘no option’ since they are not considered amenable for conventional revascularization treatment for reasons related to diffuse coronary lesions, unsuitability to chronic total occlusion mechanical revascularization, or frailty from the presence of severe comorbidities<\/em><\/strong><\/p>\n

Key companies working on Refractory Angina that are given below:-<\/em><\/strong><\/p>\n

1. <\/em><\/strong>Imbria Pharmaceuticals<\/em><\/p>\n

2. Caladrius Biosciences, Inc<\/em><\/p>\n

3. XyloCor Therapeutics, Inc<\/em><\/p>\n

Name of drugs covered that are given below:-<\/em><\/strong><\/p>\n

1. IMB-101<\/em><\/p>\n

2. Auto CD34+ Cells<\/em><\/p>\n

3. XC001<\/em><\/p>\n

Table of contents<\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Refractory Angina<\/span><\/p>\n

3. Competitive Intelligence Analysis for Refractory Angina<\/span><\/p>\n

4. Refractory Angina: Market Overview at a Glance<\/span><\/p>\n

4.1. Refractory Angina Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Refractory Angina Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Refractory Angina: Disease Background and Overview<\/span><\/p>\n

5.1. Introduction<\/span><\/p>\n

5.2. Sign and Symptoms <\/span><\/p>\n

5.3. Pathophysiology <\/span><\/p>\n

5.4. Risk Factors <\/span><\/p>\n

5.5. Diagnosis <\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. Refractory Angina Epidemiology and Patient Population<\/span><\/p>\n

7.1. Epidemiology Key Findings<\/span><\/p>\n

7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

7.3.1. Refractory Angina Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n

7.4. United States Epidemiology<\/span><\/p>\n

7.4.1. Refractory Angina Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

7.5.1. Germany Epidemiology<\/span><\/p>\n

7.5.1.1. Refractory Angina Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n

7.5.2. France Epidemiology<\/span><\/p>\n

7.5.2.1. Refractory Angina Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n

7.5.3. Italy Epidemiology<\/span><\/p>\n

7.5.3.1. Refractory Angina Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n

7.5.4. Spain Epidemiology<\/span><\/p>\n

7.5.4.1. Refractory Angina Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n

7.5.5. United Kingdom Epidemiology<\/span><\/p>\n

7.5.5.1. Refractory Angina Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

7.5.6. Japan Epidemiology<\/span><\/p>\n

7.5.6.1. Refractory Angina Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. Refractory Angina Treatment and Management<\/span><\/p>\n

8.2. Refractory Angina Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Refractory Angina Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

11.1. List of Marketed Products in the 7MM<\/span><\/p>\n

11.2. Drug Name: Company Name<\/span><\/p>\n

11.2.1. Product Description<\/span><\/p>\n

11.2.2. Regulatory Milestones<\/span><\/p>\n

11.2.3. Other Developmental Activities<\/span><\/p>\n

11.2.4. Pivotal Clinical Trials<\/span><\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

12. Emerging Therapies<\/span><\/p>\n

12.1. Key Cross<\/span><\/p>\n

12.2. Drug Name: Company Name<\/span><\/p>\n

12.2.1. Product Description<\/span><\/p>\n

12.2.2. Other Developmental Activities<\/span><\/p>\n

12.2.3. Clinical Development<\/span><\/p>\n

12.2.4. Safety and Efficacy<\/span><\/p>\n

12.2.5. Product Profile<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

13. Refractory Angina: Seven Major Market Analysis<\/span><\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Refractory Angina Market Size in 7MM<\/span><\/p>\n

13.3. Refractory Angina Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

15.1. United States: Market Size<\/span><\/p>\n

15.1.1. Refractory Angina Total Market Size in the United States<\/span><\/p>\n

15.1.2. Refractory Angina Market Size by Therapies in the United States<\/span><\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n

15.3. Germany Market Size<\/span><\/p>\n

15.3.1. Refractory Angina Total Market Size in Germany<\/span><\/p>\n

15.3.2. Refractory Angina Market Size by Therapies in Germany<\/span><\/p>\n

15.4. France Market Size<\/span><\/p>\n

15.4.1. Refractory Angina Total Market Size in France<\/span><\/p>\n

15.4.2. Refractory Angina Market Size by Therapies in France<\/span><\/p>\n

15.5. Italy Market Size<\/span><\/p>\n

15.5.1. Refractory Angina Total Market Size in Italy<\/span><\/p>\n

15.5.2. Refractory Angina Market Size by Therapies in Italy<\/span><\/p>\n

15.6. Spain Market Size<\/span><\/p>\n

15.6.1. Refractory Angina Total Market Size in Spain<\/span><\/p>\n

15.6.2. Refractory Angina Market Size by Therapies in Spain<\/span><\/p>\n

15.7. United Kingdom Market Size<\/span><\/p>\n

15.7.1. Refractory Angina Total Market Size in the United Kingdom<\/span><\/p>\n

15.7.2. Refractory Angina Market Size by Therapies in the United Kingdom<\/span><\/p>\n

15.8. Japan Market Outlook<\/span><\/p>\n

15.8.1. Japan Market Size<\/span><\/p>\n

15.8.2. Refractory Angina Total Market Size in Japan<\/span><\/p>\n

15.8.3. Refractory Angina Market Size by Therapies in Japan<\/span><\/p>\n

16. Access and Reimbursement Overview of Refractory Angina<\/span><\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About <\/strong><\/em>DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/p>\n